Pharmaceutical composition for cardio cerebrovascular diseases

A technology for cardiovascular and cerebrovascular diseases and a composition, which is applied in the field of the combination of puerarin and ferulic acid, and ginsenoside Rd, can solve the problems of using large doses and being unsafe.

Inactive Publication Date: 2012-01-11
GUIZHOU XINBANG PHARMACEUTICAL CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The purpose of the present invention is to combine several drugs with different mechanisms of action, which can significantly reduce the infarct area of ​​the brain tissue, and significantly reduce the behavioral disorder caused by brain tissue necrosis. Since the drug interaction is a synergistic interaction, it is stronger than a single drug The additive effect of the entity; solve the problem of unsafe use of large doses of individual drugs; make the drug more effective and faster

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for cardio cerebrovascular diseases
  • Pharmaceutical composition for cardio cerebrovascular diseases
  • Pharmaceutical composition for cardio cerebrovascular diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 5

[0013] Example 5 Effects on Cerebral Infarction Size

[0014] Group and Administration

[0015] Experimental animals are randomly divided into sham operation group, model group, positive drug nimodipine group, high dose 8mg / kg of pharmaceutical composition of the present invention (ie ginsenoside, puerarin, ferulic acid each account for one part) group, middle dose 4mg / kg (same as above) group, low-dose 2mg / kg (same as above) group, the animals in each group were administered sublingual vein immediately after ischemia, and then administered intraperitoneally once after 6 hours. The sham operation group and the model group were given the same amount of normal saline.

[0016] 2. Model establishment

[0017] After the rats were anesthetized, they were fixed in a supine position, the right common carotid artery (CCA), internal carotid artery (ICA) and external carotid artery (ECA) were separated, the ECA and CCA were ligated, and the distal end of the ICA was clipped with an ar...

Embodiment 2

[0026] The preparation of embodiment 2 injection

[0027] 1. Prescription:

[0028]

[0029] 2. Preparation:

[0030] Take ginsenoside-Rd, puerarin, ferulic acid, sodium chloride, 1,2-propylene glycol; dissolve sodium chloride to 500ml of 20% propylene glycol aqueous solution, add ginsenoside-Rd, salvianolic acid B, and heat at 60-70°C Stir on a water bath until fully dissolved, cool to room temperature, add the remaining amount of water for injection to 1000ml, mix well and filter with a 0.22μm filter membrane. The filtrate is filled in separate bottles, sealed, and sterilized to obtain the product.

Embodiment 3

[0031] The preparation of embodiment 3 dropping pills

[0032] 1. Prescription:

[0033]

[0034] 2. Preparation:

[0035] Take polyethylene glycol 6000, put it in a container, heat it to 70-80°C, wait until it is completely melted, and when the temperature drops to about 50°C, add ginsenoside Rd, puerarin, and ferulic acid to melt, and control the temperature at 40-80°C. 50°C, pour it into a dropping pill machine for dripping, drop it into simethicone oil, and make a dropping pill.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A pharmaceutical composition for cardio cerebrovascular diseases comprises main components of ginsenoside Rd, puerarin and ferulic acid, and can be used to obviously minimize infarction area of brain tissues and obviously decrease behavior disorder due to brain tissue necrosis, thus achieving the purpose of treating insufficiency of cerebral blood supply, cerebral thrombus formation, cerebral infarction, cerebrovascular spasm, brain dysfunction, Alzheimer disease, parkinsons syndrome, cerebral stroke, hypertension, hyperlipidemia, arteriosclerosis, coronary heart disease, angina pectoris and myocardial infarction.

Description

Technical field: [0001] The invention relates to a pharmaceutical composition for cardiovascular and cerebrovascular diseases. Specifically, the medicine involved is a combination of ginsenoside Rd, puerarin and ferulic acid, belonging to the technical field of medicines. Background technique: [0002] Cardiovascular and cerebrovascular diseases are characterized by high morbidity, disability, mortality and recurrence, and are one of the biggest killers threatening human health. According to epidemiological surveys, the incidence of cerebrovascular diseases worldwide is 1.4-200 / 100,000 population, and the average death rate is 100 / 100,000 population. With the aggravation of population aging, cerebrovascular disease, especially ischemic cerebrovascular disease has increasingly become one of the major diseases that threaten human health. It has brought a heavy burden and has attracted widespread attention from all countries in the world. The mortality rate of cerebrovascular...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(China)
IPC IPC(8): A61K31/704A61K31/352A61K31/192A61P9/00A61P9/10A61P7/02A61P25/28A61P25/16A61P9/12A61P3/06
Inventor张观福
OwnerGUIZHOU XINBANG PHARMACEUTICAL CO LTD